Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Karyopharm Therapeutics (KPTI) over the last 12 years, with Q4 2025 value amounting to $3.2 million.

  • Karyopharm Therapeutics' Short-term Investments fell 9307.03% to $3.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 million, marking a year-over-year decrease of 9307.03%. This contributed to the annual value of $3.2 million for FY2025, which is 9307.03% down from last year.
  • Karyopharm Therapeutics' Short-term Investments amounted to $3.2 million in Q4 2025, which was down 9307.03% from $8.2 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Short-term Investments' 5-year high stood at $176.3 million during Q1 2023, with a 5-year trough of $3.2 million in Q4 2025.
  • Over the past 5 years, Karyopharm Therapeutics' median Short-term Investments value was $72.2 million (recorded in 2022), while the average stood at $84.0 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' Short-term Investments surged by 27419.8% in 2022 and then tumbled by 9307.03% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Short-term Investments stood at $38.2 million in 2021, then surged by 274.2% to $142.8 million in 2022, then dropped by 2.5% to $139.2 million in 2023, then plummeted by 66.79% to $46.2 million in 2024, then plummeted by 93.07% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q4 2025, $8.2 million for Q3 2025, and $13.0 million during Q2 2025.